Why Mounjaro Doesn't Seem to Be Working for You

Are you still on a lower dose, and has enough time actually passed?

A question our prescribers hear most weeks is some version of: "I've been on Mounjaro for a month and nothing has changed." Almost always, the answer involves dose. Treatment begins at 2.5 mg, a strength that exists primarily to let your digestive system settle, not to produce measurable fat loss. The therapeutic effect builds progressively as the dose increases toward 5 mg, 7.5 mg and beyond, typically in four-week steps set by your prescriber. Expecting the first pen to do what the fifth pen does is the single most common source of disappointment with tirzepatide.

Time matters in a second way too. The trial data that generate the headline figures (roughly 20% average body-weight reduction in SURMOUNT-1) come from 72 weeks of treatment. That is well over a year. At week eight or twelve you are still in the early phase of a long programme. If you are impatient with slower early progress, you are not alone, but you are likely measuring too soon. The tirzepatide overview covers what the full trial evidence actually shows across the titration schedule.

One practical note: if side effects such as nausea have been significant, you or your prescriber may have paused a dose increase or stayed longer at a lower dose. That is clinically appropriate, but it does mean the expected weight-loss effect takes longer to arrive. Talk to your prescriber before changing anything.

Why do plateaus happen even when Mounjaro is working correctly?

The body is not a simple calculator. As weight falls, your basal metabolic rate adjusts downward, meaning you burn fewer calories at rest. This is a normal physiological response, not a fault in the medicine. Tirzepatide suppresses appetite and slows gastric emptying through its dual action on GIP and GLP-1 receptors, but it cannot override the body's adaptive response to a sustained energy deficit entirely. Plateaus (sometimes weeks where the scale barely moves) are documented in clinical trials as well as in real-world prescribing.

During a plateau, it is worth looking honestly at a few things: whether protein intake and hydration have stayed consistent, whether physical activity has changed, and whether sleep quality has deteriorated. Poor sleep raises cortisol, which can blunt appetite suppression and increase fat retention. Chronic stress does the same. None of this is about willpower. It reflects how tightly the body regulates energy balance, and it is why the weight management overview consistently frames lifestyle factors as genuinely important alongside the medicine, not as optional extras.

The NHS tirzepatide patient information also notes that response varies between individuals and that dose increases, agreed with your prescriber, are often the appropriate next step when a plateau persists at a tolerated dose. If you have been on a stable dose for more than eight weeks without any change in weight, bring that to your prescriber's attention rather than assuming the medicine has stopped working.

Could something else be interfering with how tirzepatide works?

Several factors can genuinely reduce the effectiveness of tirzepatide, and some are fixable once identified. Certain medications (most notably corticosteroids, some antipsychotics and a handful of antidiabetics) can promote weight gain or partially counteract the appetite-suppressing effect of a GLP-1 or GIP receptor agonist. Your prescriber needs to know everything you are taking, including over-the-counter items, to assess whether a co-prescription is contributing to a poor response.

Underlying conditions matter too. Hypothyroidism that is undertreated, insulin resistance, or polycystic ovary syndrome can slow or limit the weight loss that Mounjaro produces. These are not reasons to stop treatment, but they are reasons to investigate. A prescriber reviewing your case may want to check thyroid function or other markers before concluding the medicine itself is the issue. The detailed page on who Mounjaro may not work for covers specific clinical situations where the response is typically more limited.

There is also a small proportion of people who appear to respond less to GLP-1 and GIP receptor agonism for reasons that are not yet fully understood. Research is ongoing. If you have genuinely been adherent at an appropriate dose for a sustained period and results remain minimal, your prescriber may discuss whether a different treatment approach suits you better. The MHRA's public guidance on GLP-1 medicines for weight loss is a useful read if you want to understand the regulatory picture around expected outcomes. You can also explore what specifically can prevent Mounjaro from working for a focused look at the clinical factors involved.

When should you contact your prescriber, and what should you tell them?

If Mounjaro does not seem to be working, the worst response is to quietly stop taking it or to change the dose yourself. Both carry risks and neither gives your prescriber the information they need. The right move is a clear, honest conversation: how long you have been on your current dose, what your weight has done since you started, whether side effects have limited your titration, and whether anything in your health or other medications has changed.

For patients accessing treatment through a regulated service, repeat prescriptions should come with a clinical review at each stage. At nume, a GPhC-registered prescriber personally reviews your case before any dose change or repeat is issued, which is the point at which questions about response and titration are exactly the right things to raise. If you are on treatment elsewhere and struggling to get that kind of review, it is worth asking directly. Dose increases are not handed out automatically; they follow clinical assessment of your response, tolerability and overall health picture.

A note on expectations: even a 5% reduction in body weight produces measurable clinical benefits for blood pressure, blood glucose and joint load. Mounjaro's trial results at the highest doses are striking, but a clinically meaningful response does not require reaching the headline figure. If you are unsure whether your response is adequate, your prescriber is the person best placed to judge that in the context of your full medical picture. You can read more about the specific question of whether Mounjaro can simply not work for some people, and what that means practically. For a broader look at why tirzepatide might not be working in your specific situation, that page covers the question from several additional angles, and if you want to explore the related question of why tirzepatide does not work for some people, that page examines the issue from a drug-specific perspective with additional clinical detail. If you think private treatment through a clinically supervised route could help, you can check your eligibility with our prescribers at no cost.